Clinical Trial Update: A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating venetoclax with low-dose hypomethylating agent, G-CSF, and azacitidine as first-line treatment for newly diagnosed elderly AML patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• HHT (hypomethylating agent (unspecified))
• Venetoclax (venetoclax)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: UNKNOWN